A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)

Key Inclusion Criteria: * Aged 18 years or older * A diagnosis of Rheumatoid Arthritis based on ACR/EULAR 2010 classification criteria, for at least 3 months before participating in the trial * Must be receiving treatment with at least 1, but not more than 2 csDMARDs for at least 3 months and be on stable dosages for at least 8 weeks prior to joining and throughout the trial * Have had an inadequate response to, or loss of response or intolerance to at least 1 conventional synthetic DMARD (csDMARD), biologic DMARD (bDMARD), or targeted synthetic DMARD (tsDMARD) treatment Key Exclusion Criteria: * History of an inflammatory joint disease other than Rheumatoid Arthritis * Prior exposure to a PD-1 or PD-L1 agonist, antagonist, or modulator * History of cancer within the last 5 years (except for some skin cancers) * Any known or suspected condition that would compromise immune status * Pregnant or breastfeeding women